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Introduction: Hematopoietic cell transplantation (HCT) is
a potential cure for certain hematologic malignancies.
However due to risks of complications and mortality, this
treatment option is limited to patients with minimal co-
morbidities. There are few data on patients with systolic
heart failure undergoing HCT. We performed a case control
study evaluating the impact of pre-HCT systolic heart failure
on outcomes.
Methods: We studied 48 subjects with systolic heart failure
deﬁned as left-ventricular ejection fraction (LVEF) <50% and
48 controls (matched by age, gender, conditioning regimen,
and number of transplanted units) with LVEF >¼ 50% un-
dergoing HCT at the University of Minnesota between 2002-
2012. Treatment complications and mortality at 100 days, as
well as overall survival (OS) after HCT at 100 days, 12 months
and 24 months were determined including use of beta-
blockers and angiotensin converting enzyme (ACE)
inhibitors.
Results: The median pre-transplant age was 51.9 (19.1-
69.2) years in the study group and 54.5 (20.7-72.5) years in
the controls; each including 31 males (63.3%) and 18 fe-
males (36.7%). In both groups, 9 patients (18.8%) received
myeloablative conditioning regimen and 39 (81.3%) had
reduced intensity conditioning. The median LVEF was 45%
(27.5-49%) for the study group and 60% (50-69%) for the
control. Beta-blocker use at the time of HCT (32.7% in the
study group vs. 4.1% in the control; p<0.01) and ACE-in-
hibitor use (30.6% in the study group vs. 6.1% in the control;
p<0.01) were more common in the study group compared
to the control group. Treatment related mortality (TRM) at
day 100 was identical with a cumulative incidence of 7 of
48 (15%) in the study (RR 15%, 95% CI 5-24%) and 7 of 48
(15%) in the control (RR 15%, 95% CI 5-25%) (p¼0.88). There
was no signiﬁcant difference in the 2-year OS between the
study group (n¼26, 54%, CI 39-67%) compared to the con-
trol group (n¼29, 60%, CI 45-72%) (p¼ 0.43). An LVEF >¼
43% was a threshold for improved OS at 1 year (HR 0.36,
95% CI 15-87%; p¼0.02). There was no signiﬁcant increase
in the incidence of minor (non-life-threatening) cardiac
complications (12.2% in the study vs. 8.2% in the control,
p¼0.50) or serious (life-threatening or fatal) cardiac com-
plications (4.1% in the study group vs. 2.0% in the control,
p¼0.56) between groups. The use of beta-blockers (HR
0.43, 95% CI 20-89%, p¼0.02) and ACE-inhibitors (HR 0.34,
95% CI 16-70%, p<0.01) at the time of HCT was associated
with improved OS at 1 year.
Conclusion: Our results suggest that patients with
reduced systolic heart function, particularly with an EF >¼
43%, should not be excluded from HCT. However, a LVEF <
43% was associated with reduced OS at 1 year. Addition-
ally, beta-blockers and ACE-inhibitors use should be part
of the treatment plan for this population when undergo-
ing HCT.23
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Introduction: High-dose, PTCy is an effective strategy for
GVHD prevention after allogeneic blood or marrow trans-
plantation (alloBMT), but the impact of PTCy on long-term
outcomes, particularly relapse, has not been assessed. Here
we report outcomes for 291 consecutive adult patients at
Johns Hopkins treated with PTCy as sole GVHD prophylaxis.
Methods: All adult patients treated with this approach from
its commencement in 2004 through 2011 were included.
Datawere locked on June 30, 2013. Median follow-upwas 3.7
years (range 0.3-8.3) for surviving patients. Allograft donors
were HLA-matched-related for 60% and HLA-matched-un-
related for 40%. All allografts were T cell replete and bone
marrow derived in all but onewho received peripheral blood
stem cells. Myeloablative conditioning (MAC) was busul-
fan(Bu)/Cy in 248 patients (85%), Bu/ﬂudarabine in 42 (14%),
and Cy/total body irradiation in 1 (0.3%).
Median patient age was 49 years (range 18-66), and me-
dian HCT-CI score was 2 (range 0-12) with 39% having a score
of 3. At the time of transplant, 31% of patients were not in
remission and an additional 28% had minimal residual dis-
ease. Diseases included 138 AML (47%), 43 ALL (15%), 28 MDS
(10%), 31 non-Hodgkin lymphomas (11%), 24 CML (8%), 13
Hodgkin lymphoma (4%), 9 multiple myeloma (3%), and 5
other diseases (2%). High-risk disease characteristics of AML
patients included adverse cytogenetics by the reﬁned MRC
criteria in 58 (42%), Flt3/ITD positivity in 37 (27%), and sec-
ondary from antecedent hematologic disorder in 51 (37%).
Forty-four percent of ALL patients were Philadelphia chro-
mosome (Ph) positive.
Results: Primary graft failure occurred in 9 patients (3%). By
competing-risk analysis, the cumulative incidences (CI) of
non-relapse mortality at 1 and 3 years were 17% and 18%,
respectively. Venocclusive disease occurred in 17 patients
(6%) and was fatal in 4 patients (1%).
The CIs of grades II-IV and III-IV acute GVHDwere 44% and
14%, respectively, and acute GVHDwas the cause of death in 6
patients (2%). The CIs of grades III-IV acute GVHD were not
different between matched-related or matched-unrelated
alloBMT. The total CI of chronic GVHD was 11% (8% for
matched-related and 16% for matched-unrelated, p¼0.03).
The CI of relapse at 3 years for all patients was 39% (37%
AML, 33% ALL, 40% MDS). The 3-year disease-free survival
(DFS) probability for all patients was 42% (43% AML, 55% ALL,
53% MDS). The 3-year overall survival (OS) probability for all
patients was 58% (53% AML, 74% ALL, 67% MDS). DFS and OS
were similar regardless of donor relatedness. A statistically
signiﬁcant impact of Flt3/ITD in AML or Ph+ in ALL on DFS or
OS was not detected.
Conclusion: The use of PTCy as sole GVHD prophylaxis after
MAC HLA-matched alloBMT is associated with a favorable
toxicity proﬁle and affords long-term disease control for a
large subset of patients with poor-risk hematologic malig-
nancies in the absence of chronic GVHD.
